vs
Side-by-side financial comparison of INSTEEL INDUSTRIES INC (IIIN) and IOVANCE BIOTHERAPEUTICS, INC. (IOVA). Click either name above to swap in a different company.
INSTEEL INDUSTRIES INC is the larger business by last-quarter revenue ($159.9M vs $86.8M, roughly 1.8× IOVANCE BIOTHERAPEUTICS, INC.). On growth, INSTEEL INDUSTRIES INC posted the faster year-over-year revenue change (23.3% vs 17.7%). INSTEEL INDUSTRIES INC produced more free cash flow last quarter ($-2.2M vs $-61.9M). Over the past eight quarters, IOVANCE BIOTHERAPEUTICS, INC.'s revenue compounded faster (1001.6% CAGR vs 12.0%).
Insteel Industries Inc is a leading U.S. manufacturer of steel reinforcing products including welded wire reinforcement and steel fibers. It primarily serves non-residential construction, infrastructure, and precast concrete segments across North America, delivering high-performance reinforcement solutions for various construction projects.
Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.
IIIN vs IOVA — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $159.9M | $86.8M |
| Net Profit | $7.6M | — |
| Gross Margin | 11.3% | 67.4% |
| Operating Margin | 6.0% | -84.7% |
| Net Margin | 4.7% | — |
| Revenue YoY | 23.3% | 17.7% |
| Net Profit YoY | 602.4% | — |
| EPS (diluted) | $0.39 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $159.9M | $86.8M | ||
| Q3 25 | $177.4M | $67.5M | ||
| Q2 25 | $179.9M | $60.0M | ||
| Q1 25 | $160.7M | $49.3M | ||
| Q4 24 | $129.7M | $73.7M | ||
| Q3 24 | $134.3M | $58.6M | ||
| Q2 24 | $145.8M | $31.1M | ||
| Q1 24 | $127.4M | $715.0K |
| Q4 25 | $7.6M | — | ||
| Q3 25 | $14.6M | $-91.3M | ||
| Q2 25 | $15.2M | $-111.7M | ||
| Q1 25 | $10.2M | $-116.2M | ||
| Q4 24 | $1.1M | — | ||
| Q3 24 | $4.7M | $-83.5M | ||
| Q2 24 | $6.6M | $-97.1M | ||
| Q1 24 | $6.9M | $-113.0M |
| Q4 25 | 11.3% | 67.4% | ||
| Q3 25 | 16.1% | 43.0% | ||
| Q2 25 | 17.1% | 5.5% | ||
| Q1 25 | 15.3% | -0.8% | ||
| Q4 24 | 7.3% | 68.7% | ||
| Q3 24 | 9.1% | 46.2% | ||
| Q2 24 | 10.6% | -0.8% | ||
| Q1 24 | 12.3% | — |
| Q4 25 | 6.0% | -84.7% | ||
| Q3 25 | 10.8% | -140.7% | ||
| Q2 25 | 11.0% | -189.8% | ||
| Q1 25 | 8.3% | -245.8% | ||
| Q4 24 | 1.1% | -117.5% | ||
| Q3 24 | 4.5% | -152.1% | ||
| Q2 24 | 6.0% | -327.6% | ||
| Q1 24 | 7.0% | -16464.6% |
| Q4 25 | 4.7% | — | ||
| Q3 25 | 8.2% | -135.3% | ||
| Q2 25 | 8.4% | -186.2% | ||
| Q1 25 | 6.4% | -235.5% | ||
| Q4 24 | 0.8% | — | ||
| Q3 24 | 3.5% | -142.7% | ||
| Q2 24 | 4.5% | -312.2% | ||
| Q1 24 | 5.4% | -15800.8% |
| Q4 25 | $0.39 | — | ||
| Q3 25 | $0.74 | — | ||
| Q2 25 | $0.78 | $-0.33 | ||
| Q1 25 | $0.52 | $-0.36 | ||
| Q4 24 | $0.06 | $-0.24 | ||
| Q3 24 | $0.24 | $-0.28 | ||
| Q2 24 | $0.34 | $-0.34 | ||
| Q1 24 | $0.35 | $-0.42 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $15.6M | $297.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $358.8M | $698.6M |
| Total Assets | $456.1M | $913.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $15.6M | $297.0M | ||
| Q3 25 | $38.6M | $300.8M | ||
| Q2 25 | $53.7M | $301.2M | ||
| Q1 25 | $28.4M | $359.7M | ||
| Q4 24 | $36.0M | $323.8M | ||
| Q3 24 | $111.5M | $397.5M | ||
| Q2 24 | $97.7M | $412.5M | ||
| Q1 24 | $83.9M | $356.2M |
| Q4 25 | $358.8M | $698.6M | ||
| Q3 25 | $371.5M | $702.3M | ||
| Q2 25 | $356.2M | $698.5M | ||
| Q1 25 | $341.4M | $767.9M | ||
| Q4 24 | $331.6M | $710.4M | ||
| Q3 24 | $350.9M | $773.5M | ||
| Q2 24 | $346.0M | $768.5M | ||
| Q1 24 | $340.6M | $680.0M |
| Q4 25 | $456.1M | $913.2M | ||
| Q3 25 | $462.6M | $904.9M | ||
| Q2 25 | $471.9M | $907.4M | ||
| Q1 25 | $421.9M | $966.7M | ||
| Q4 24 | $404.7M | $910.4M | ||
| Q3 24 | $422.6M | $991.1M | ||
| Q2 24 | $414.6M | $964.3M | ||
| Q1 24 | $397.2M | $869.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-701.0K | $-52.6M |
| Free Cash FlowOCF − Capex | $-2.2M | $-61.9M |
| FCF MarginFCF / Revenue | -1.4% | -71.3% |
| Capex IntensityCapex / Revenue | 0.9% | 10.7% |
| Cash ConversionOCF / Net Profit | -0.09× | — |
| TTM Free Cash FlowTrailing 4 quarters | $439.0K | $-336.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-701.0K | $-52.6M | ||
| Q3 25 | $-17.0M | $-78.7M | ||
| Q2 25 | $28.5M | $-67.4M | ||
| Q1 25 | $-3.3M | $-103.7M | ||
| Q4 24 | $19.0M | $-73.3M | ||
| Q3 24 | $16.2M | $-59.0M | ||
| Q2 24 | $18.8M | $-98.4M | ||
| Q1 24 | $1.4M | $-122.3M |
| Q4 25 | $-2.2M | $-61.9M | ||
| Q3 25 | $-18.7M | $-89.5M | ||
| Q2 25 | $26.9M | $-74.9M | ||
| Q1 25 | $-5.5M | $-109.9M | ||
| Q4 24 | $16.3M | $-77.5M | ||
| Q3 24 | $14.5M | $-61.3M | ||
| Q2 24 | $15.5M | $-98.9M | ||
| Q1 24 | $-580.0K | $-126.5M |
| Q4 25 | -1.4% | -71.3% | ||
| Q3 25 | -10.6% | -132.7% | ||
| Q2 25 | 15.0% | -124.9% | ||
| Q1 25 | -3.5% | -222.8% | ||
| Q4 24 | 12.6% | -105.1% | ||
| Q3 24 | 10.8% | -104.6% | ||
| Q2 24 | 10.7% | -317.9% | ||
| Q1 24 | -0.5% | -17685.3% |
| Q4 25 | 0.9% | 10.7% | ||
| Q3 25 | 1.0% | 16.1% | ||
| Q2 25 | 0.9% | 12.4% | ||
| Q1 25 | 1.4% | 12.6% | ||
| Q4 24 | 2.1% | 5.7% | ||
| Q3 24 | 1.3% | 3.9% | ||
| Q2 24 | 2.2% | 1.4% | ||
| Q1 24 | 1.5% | 583.4% |
| Q4 25 | -0.09× | — | ||
| Q3 25 | -1.17× | — | ||
| Q2 25 | 1.88× | — | ||
| Q1 25 | -0.32× | — | ||
| Q4 24 | 17.56× | — | ||
| Q3 24 | 3.48× | — | ||
| Q2 24 | 2.86× | — | ||
| Q1 24 | 0.20× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
IIIN
| Welded Wire Reinforcement | $108.4M | 68% |
| PC Strand | $51.6M | 32% |
IOVA
| Amtagvi | $64.9M | 75% |
| Proleukin | $21.9M | 25% |
